Moderna
was climbing Monday immediately after an analyst at Jefferies upgraded the stock citing self esteem in the vaccine maker’s growth prospects that are not linked to the Covid-19 vaccine.
Jefferies analyst Michael Yee upgraded shares of Moderna (ticker: MRNA) to Buy from Keep and increased his 12-thirty day period selling price target on the inventory to $275 from $170. For Moderna, Yee stated he sees a “significant new pipeline story and catalysts ahead.”
